blinatumomab,ponatinib
incyte,astellas,amgen,takeda,otsuka
['#all ,(-alli),(-allogenic)', 'ponatinib', 'blinatumomab']
2) ponatinib + blinatumomab in ph+ #all showed very promising results in newly diagnosed and relapsed/refractory patients with high rates of cmr. 
Hematologist. Leukemia, clonal hematopoiesis and epigenetics.